Discussing expectations for clinical oncology conference ASCO, with Eric Schmidt, Cowen & Co. biotech analyst. He weighs in on data from Puma Biotech, AstraZeneca and Incyte.» Read More
European pharmaceutical Roche reported a better-than-expected 25 percent increase in fourth-quarter net profit Wednesday on strong sales of its cancer drugs, despite lower sales of its key influenza drug Tamiflu.
Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...
Merck on Wednesday reported a fourth-quarter loss due to charges from a costly settlement related to its withdrawn Vioxx arthritis drug, but results soundly beat Wall Street forecastsand lifted its shares 2 percent.
"Dendreonians" were hoping the Provenge controversy might come up for discussion at the House Energy and Commerce Committee's Subcommittee on Oversight and Investigations hearing today.
Eli Lilly posted a higher fourth-quarter profit Tuesday. The pharmaceutical firm cited lower taxes and better-than-expected drug sales -- especially sales of its newer formulations for diabetes and cancer. John Lechleiter, president and chief operating officer -- and Lilly's CEO as of April 1 -- gave CNBC his strong earnings outlook.
Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.
Eli Lilly Tuesday said fourth-quarter profit rose on lower taxes and better-than-expected sales of its medicines, including its newer treatments for depression, diabetes and cancer.
In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.
A $4 billion company I've never covered before, Inverness Medical Innovations, is making news this morning with a $900 million acquisition of another company I've never covered--Matria Healthcare, Inc. But that's not why I'm blogging about Inverness.
I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...
In the wake of my semantic disagreement with Amgen over whether it beat, met or missed its earnings pre-announcement earlier this month, analysts are putting out research notes to clients on the company's results, guidance and new drug data and blog readers are sending emails about my take on the full year 2007 number.
I just got back to my desk after doing a breaking news alert on Amgen's earnings. To sum up, I characterized the report as a mixed bag. The anemia drug sales weren't as bad as expected. Overall revenue was higher than consensus. And fourth quarter earnings per share was three cents higher than the Street.
Amgen reported on Thursday that its fourth-quarter profit edged higher, on a reversal of declining sales of its anemia drugs that have been hit with safety concerns and new restrictions on their use and insurance reimbursements.
ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.
After yesterday's beat and boost by drug giant Pfizer and a late-day rally in the stock, analysts are providing clients their take on the numbers as the shares traded lower in the early going. Deutsche Bank's Barbara Ryan is keeping her long-standing "Buy" rating on PFE, even though she told me recently she's been "long and wrong" on the stock.
The show was over, but Cramer kept going. Don't miss his in-depth answers to audience questions about Merck, Target and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
As I write this at the start of the second hour of regular trading, Pfizer is hangin' on to a small gain. It's the only big pharma stock trading higher this morning and for a moment after the opening bell it was the only Dow component in the green. (Merck and Schering-Plough, still reeling from the Vytorin/Zetia study, are getting pummeled again in the early going--each down more than a buck.)
Pfizer Wednesday reported a higher-than-expected fourth-quarter profit, helped by lower taxes, a weak dollar and growing demand for its drugs for nerve pain, kidney cancer and smoking cession.
This press release and letters to the CEOs of MRK and SGP from the House Energy and Commerce Committee just arrived in my inbox:
I'm blogging today from outside the New York Stock Exchange where I'm trying to round up "man-on-the-(Wall) street" reaction to the markets. In the meantime, back on the beat, for the second day Merck and Schering-Plough have taken out two-page ads in major newspapers defending their cholesterol drugs Zetia and Vytorin whose efficacy is under attack.